My heart is racing. Managing Complex Cases. Case 1. Case 1

Similar documents
Diagnosis and Treatment of Tuberculosis, 2011

Tuberculosis: Where Are We Now?

Diagnosis and Medical Management of Latent TB Infection

Northwestern Polytechnic University

Contact Investigation and Prevention in the USA

Case 1: Clinical Presentation

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

Tuberculosis: A Provider s Guide to

The diagnosis of active TB

Treatment of Tuberculosis

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Fundamentals of Tuberculosis (TB)

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB in the Patient with HIV

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

TB Intensive San Antonio, Texas May 7-10, 2013

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Treatment of Tuberculosis, 2017

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

Case 1. Background. Presenting Symptoms. Schecter Case1 Differential Diagnosis of TB 1

Treatment of Tuberculosis

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Diagnosis of tuberculosis in children

Tuberculosis Intensive

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

TB in Corrections Phoenix, Arizona

Screening and Treatment Recommendations for Persons Exposed to MDR TB

TB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:

Property of Presenter. Not for Reproduction DENVER TB COURSE: CHALLENGING CLINICAL PRESENTATIONS

Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer

Tuberculosis and Diabetes Dec. 10, 2009 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18

8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Latent TB Infection (LTBI)

Tuberculosis Tools: A Clinical Update

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

Challenges in Management: Solid Organ Transplantation & Tuberculosis

The Diagnosis of Active TB. Deborah McMahan, MD TB Intensive September 28, 2017

Rehuka Khurana, MD, MPH has the following disclosures to make:

New Tuberculosis Guidelines. Jason Stout, MD, MHS

TB Nurse Assessment. Ginny Dowell, RN, BSN October 21, 2015

ESCMID Online Lecture Library. by author

Latent TB, TB and the Role of the Health Department

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

TB Nurse Case Management San Antonio, Texas April 9-11, 2013

TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012

TB in the Correctional Setting Florence, Arizona October 7, 2014

Errors in Dx and Rx of TB

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Summary Statistics of Reported and Verified Cases of Tuberculosis in San Joaquin County in 2012, (N=44) County Rate = 6.3 Cases per 100,000 Population

New Standards for an Old Disease:

Tuberculosis Populations at Risk

Profile of Tuberculosis Infection among Current HIV+ Patients at the Philippine General Hospital

TB Grand Rounds. Reynard McDonald, MD & Henry Fraimow, MD January 30, Outline

Communicable Disease Control Manual Chapter 4: Tuberculosis

Disclosure. Objectives

Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)

2018 Tuberculosis Clinical Intensive: Infection Prevention & Control. > No disclosures

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University

Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016

Chapter 22. Pulmonary Infections

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

TB and Comorbidities Adriana Vasquez, MD April 12, 2018

TB 101 Disease, Clinical Assessment and Lab Testing

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

Diagnosing TB in HIV Co- infected PaAents

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011

The Epidemiology of Tuberculosis in Minnesota,

SA TB Guidelines The interface with Advanced Clinical Care

has the following disclosures to make:

INDEX CASE INFORMATION

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

TB Clinical Guidelines: Revision Highlights March 2014

TB Laboratory for Nurses

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

TB trends and TB genotyping

LTBI Treatment and Anti TNF alpha

The Elimination of Tuberculosis. Richard E. Chaisson, MD. Center for TB Research Center for AIDS Research Johns Hopkins University

TB Contact Investigation

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

State of the State in TB Control

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2013

TB BASICS: PRIORITIES AND CLASSIFICATIONS

TB in Corrections Phoenix, Arizona

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

Transcription:

Managing Complex Cases My heart is racing Amee Patrawalla, MD April 7, 2017 Case 1 Rutgers, The State University of New Jersey Rutgers, The State University of New Jersey Case 1 29 year old physician from South Asia who presents with palpitations and dizziness while at work Her pulse is 200 beats per minute EKG shows supraventricular tachycardia which coverts to normal sinus rhythm with adenosine Case 1 She had a similar episode 3 years ago In retrospect, she has had a dry cough x 2-3 months but has been too busy to get it evaluated No other symptoms TST negative 6 months previously Routine labs are normal 1

Which of the following would you do? A. Treat for community acquired pneumonia and repeat CXR in 1 month B. Place in respiratory isolation and obtain sputa for bacterial and mycobacterial cultures C. Treat her empirically for tuberculosis disease D. Obtain baseline pulmonary function testing and begin treatment for sarcoidosis Case 1 Induced sputum x 3 AFB smear negative QuantiFERON Gold + Bronchoscopy performed BAL smear negative MTB PCR failed Started on multidrug TB therapy and remained on home isolation for 2 weeks Cultures MTB positive 4 weeks later 2

Smear-Negative TB Sputum smear microscopy sensitivity ~ 50% Even lower in HIV and children 5000-10,000 bacilli = smear positive Increasingly common, especially in high HIV settings 35 40% of US cases Shah, IJTLD, 2012 Tostmann, CID, 2008 Smear Negative TB (1993 2008, US) Smear Negative TB Associated with SNTB Incarcerated Foreign birth Lower mortality HIV Age < 14 Not clear association Homeless IDU Alcohol use Less Likely to have SNTB Hispanic African American Smear negative TB accounts for 13-22% of TB transmission Up to 1/4 the number of cases as smear positive index cases Associated with diagnostic and treatment delays, which may lead to additional transmission Shah, IJTLD, 2012 Tostmann, CID, 2008 (Netherlands) Hernandez-Garduno, 2004 (Vancouver) Behr et al, Lancet, 1999 (San Francisco) 3

Smear-Negative TB Is common and transmissible Infection control measures are necessary Contact tracing is essential, but is often delayed Rapid diagnostic tests are moderately sensitive and can speed up diagnosis, isolation and treatment Treatment similar to smear positive TB Empiric therapy may be needed I m coughing a lot recently Case 2 Rutgers, The State University of New Jersey Case 2 45 y.o. incarcerated woman brought to hospital ED Reports cough, fevers, sweats and weight loss for 2 months History of injection drug use HIV negative No prior treatment for TB AFB Smear negative x 3 4

At this point you would A. Treat for pneumonia and transfer back to prison B. Maintain respiratory isolation and start empiric TB treatment C. Do nothing and await culture results, knowing culture is more sensitive than smear D. Refer to Surgery for an open lung biopsy Case 2 AFB smear negative Started on multidrug TB regimen Cultures remain negative with minimal improvement in CXR Symptoms improve Culture Negative Pulmonary TB Clinical and radiologic picture of active TB Cultures remain negative Paucibacillary Incorrect specimen processing Temporal variation in bacteria shedding Culture negative TB Perform at least 3 quality sputum exams Consider other diagnostics such as bronchoscopy, rapid tests Up to 15-20% of reported TB cases in US 5

Culture negative TB Culture negative TB 4 month regimen of isoniazid and rifampin has been shown to have a 1.2% relapse rate GeneXpert MTB/RIF may have some utility ATS/IDSA/CDC 2003 Dutt, 1989 Marlowe, 2011 Zeka, 2011 Case 3 I have a nagging dry cough Case 3 58 y.o. Filipino woman who underwent orthotopic liver transplantation about 1 year previously Persistent dry cough x 3 months 10 lb. weight loss No fevers, chills or other symptoms Rutgers, The State University of New Jersey 6

Case 3: Past Medical History TST + in past - CXR normal - Not treated Hepatitis B with Hepatocellular carcinoma (HCC) diagnosed 1.5 years ago OLT 1 year previously Recurrent HCC on sorafenib, s/p HACE Other meds: prednisone, sirolimus, tenofovir, trimethoprim/sulfamethoxazole Case 3: Microbiology Smear Culture Sensi 8/4 Doubtful MTB pansens 8/5 Neg Neg 8/7 Neg (BAL) MTB 8/21 1+ MTB Which drug is most likely to significantly interact with patient s current medications? A. Ethambutol B. Pyrazinamide C. Rifampin D. Rifabutin E. None will interact Case 4: Treatment Treatment was complicated by multiple drug interactions, intolerance and underlying active liver disease Multiple treatment interruptions and changes in regimen Additional invasive procedures Unstable, multifactorial liver disease Resulted in tremendous anxiety and disruption for patient 7

U/L Case 4: Lab data 140 120 100 80 60 40 20 HACE RBT, IPE initiated RBT, IPE Meds Held RBT, INH Rad. Worsening: RBT,IPE, Moxi, PAS Meds held AST ALT Solid Organ Transplant and TB TB in SOT patients is 20-74 times higher than general population 1.2%-6.4% prevalence in developed countries Up to 12% in endemic countries Most cases occur in 1 st year after transplant Reported mortality as high as 20-30% Not a well studied field 6/22/2009 7/6/2009 7/20/2009 8/3/2009 8/17/2009 8/25/2009 9/2/2009 9/10/2009 9/17/2009 9/21/2009 10/5/2009 10/19/2009 11/2/2009 11/16/2009 11/30/2009 12/10/2009 12/14/2009 12/16/1009 12/28/2009 1/11/2010 1/25/2010 2/8/2010 2/22/2010 3/15/2010 3/29/2010 4/12/2010 4/26/2010 5/17/2010 5/28/2010 American Journal of Transplantation 2013; 13: 68 76 SOT and TB Disease Recognized risk factors Prior residence in high incidence country Prior untreated TB CXR with evidence of healed TB Transplant rejection resulting in increased immunosuppression Dialysis duration (Renal) Hepatitis C (Renal) SOT and TB Disease Vast majority are reactivation < 5% donor derived infections Up to ½ of cases are disseminated or EP Classic cavitary PTB rare Negative pre-transplant TST common in posttransplant cases Use TST + IGRA in high risk settings Use CXR and CT results in high risk but negative TST/IGRA 8

SOT and TB Treatment TB infection Treat if old, untreated disease, donor TST+ or recent contact, or recipient has recent exposure May not tolerate IPT until after transplant (e.g. liver) Rifampin x 4 months if can complete pre-sot Increase in LFTs may not be due to INH in pts with OLT INH RPT viable option TB disease Rifabutin fewer drug interactions Summary Smear negative, culture negative TB present diagnostic and treatment challenges Maintain index of suspicion, especially in known risk groups Managing comorbidities requires multidisciplinary approach Partner with and educate those in community most likely to see certain risk groups American Journal of Transplantation 2013; 13: 68 76 9